Samlyn Capital, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Samlyn Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$83.14 - $145.99 $12.9 Million - $22.6 Million	-154,706 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$65.07 - $98.24 $15.5 Million - $23.4 Million	-238,250 Reduced 60.63%	154,706 $13.3 Million
Q3 2020 Nov 16, 2020	SELL	$59.04 - $77.95 $8.48 Million - $11.2 Million	-143,574 Reduced 26.76%	392,956 $25.5 Million
Q2 2020 Aug 14, 2020	BUY	$29.01 - $74.23 $15.6 Million - $39.8 Million	536,530 New	536,530 $39.2 Million
Q2 2019 Aug 14, 2019	SELL	$39.79 - $67.01 $29 Million - $48.9 Million	-729,178 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$34.52 - $53.29 $6.64 Million - $10.3 Million	-192,358 Reduced 20.87%	729,178 $37.5 Million
Q4 2018 Feb 14, 2019	BUY	$29.75 - $42.9 $6.77 Million - $9.76 Million	227,432 Added 32.77%	921,536 $34.1 Million
Q3 2018 Nov 14, 2018	BUY	$32.79 - $43.0 $10.1 Million - $13.2 Million	307,380 Added 79.48%	694,104 $26.1 Million
Q2 2018 Aug 14, 2018	SELL	$23.62 - $42.29 $344,804 - $617,349	-14,598 Reduced 3.64%	386,724 $15.3 Million
Q1 2018 May 15, 2018	BUY	$22.49 - $34.56 $9.03 Million - $13.9 Million	401,322 New	401,322 $10.3 Million

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.18B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Samlyn Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samlyn Capital, LLC with notifications on news.